Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce its latest results for its novel blood test for oesophageal adenocarcinoma will be presented tomorrow at the 19th ISDE World Congress for Esophageal Diseases.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that its subsidiary OxiDx Pty Ltd has been granted a patent in Japan for its platform technology to measure oxidative stress.
Proteomics International Laboratories Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was AUD 6.18 million compared to AUD.
It has been a pivotal year for Proteomics International Laboratories Ltd (ASX:PIQ), with the signing of a landmark deal to bring our PromarkerD test for diabetic kidney disease to patients in the United States.